DeuterOncology, founded in 2020 in Liège, Belgium, is developing DO-2, a novel deuterated MET kinase inhibitor. Backed by strong preclinical data, DO-2 is in Phase I trials to become a best-in-class cancer therapy.
Dr Timothy Perera, CEO
DeuterOncology
Afinis Business Centre,
Clos Chanmurly 13,
Liege 4000,
Belgium
+32473558353
tperera@deuteroncology.com
Media Room Powered By Press Advantage
Liège, Liège - September 08, 2025 - PRESSADVANTAGE - DO-2 is a Best in Class MET kinase inhibitor that completed...
Read More
